Cardium Therapeutics (AMEX: CXM) reported today that its Cardium Biologics division provided an update on plans for the continuing commercial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE